利科林通过激活STING途径和刺激抗瘤免疫反应来抑制非小细胞肺癌的进展
Ze-Bo Jiang1, Cong Xu2, Pan Xu1
1Zhuhai Hospital of Integrated Traditional Chinese & Western Medicine, Zhuhai, Guangdong, China.
Chemical biology & drug design
|December 21, 2024
概括
莱科林 (LYD) 通过通过ROS触发细胞死亡并激活STING通路来对抗非小细胞肺癌 (NSCLC). 这种天然化合物还抑制了生长蛋白,并增强了T细胞,显示了NSCLC治疗的前景.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 药用植物中的基烯Lycorine (LYD) 显示出抗癌作用,但其NSCLC机制尚不清楚.
研究的目的:
- 为了阐明Lycorine (LYD) 在非小细胞肺癌 (NSCLC) 中的抗瘤机制.
- 研究LYD对NSCLC增殖,细胞亡和免疫调节的影响.
主要方法:
- 评估LYD对NSCLC细胞增殖和细胞亡的影响,测量反应性氧物种 (ROS) 水平.
- 利用N-乙半氨酸 (NAC) 阻止ROS,并评估了STING通路激活和化学激素表达 (CXCL10,CXCL9,CCL5).
- 研究了LYD对P70S6K和S6K蛋白水平的影响,并在NSCLC小鼠模型中评估了体内抗瘤活性.
主要成果:
- 通过增加细胞内ROS,LYD显著降低了NSCLC的扩散和诱导的亡.
- 通过NAC抑制ROS逆转了LYD的亡效应,增加了细胞活力.
- LYD激活了STING通路,高调化学激素 (CXCL10,CXCL9,CCL5),并降低了P70S6K/S6K蛋白.
- 在体内,LYD抑制了瘤生长,并在NSCLC小鼠模型中增加了CD8+T细胞.
结论:
- 通过诱导ROS介导的亡并调节STING通路和化学激素,LYD对NSCLC表现出强大的抗癌特性.
- LYD抑制关键细胞生长蛋白 (P70S6K,S6K) 并通过CD8+ T细胞增强抗瘤免疫力.
- 莱科林显示出作为NSCLC治疗治疗剂的显著潜力.
关键词:
CD8+ T T8+ CD8+ T T8+ CD8+ T T T8+ CD8+ CD8+ T T T8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ CD8+ T T莱科林 (Lycorine) 是一种可怕的药物.刺痛是一种刺痛.非小细胞肺癌的肺癌.更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Positive Regulator Molecules
105.7K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.7K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


